These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 392372)

  • 41. Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes.
    Siitonen T; Savolainen ER; Koistinen P
    Leukemia; 1994 Apr; 8(4):631-7. PubMed ID: 7512174
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic implications of basophil differentiation in chronic myeloid leukemia.
    Denburg JA; Browman G
    Am J Hematol; 1988 Feb; 27(2):110-4. PubMed ID: 3422537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Leukocyte alkaline phosphatase and glucose-6-phosphate-dehydrogenase of the erythrocytes in differential diagnosis of chronic myeloproliferative diseases (author's transl)].
    Hennemann HH; Schief A
    Med Klin; 1974 Aug; 69(34):1359-63. PubMed ID: 4530151
    [No Abstract]   [Full Text] [Related]  

  • 44. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Platelet function and arachidonate metabolism in patients with myeloproliferative disorders.
    Okuma M
    Nihon Ketsueki Gakkai Zasshi; 1980 Dec; 43(6):1139-44. PubMed ID: 6800179
    [No Abstract]   [Full Text] [Related]  

  • 46. Basophilic chronic granulocytic leukaemia with hyperhistaminaemia.
    Rosenthal S; Schwartz JH; Canellos GP
    Br J Haematol; 1977 Jul; 36(3):367-72. PubMed ID: 268209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Automated analysers underestimate atypical basophil count in myeloid neoplasms.
    Shah HP; Tormey CA; Siddon AJ
    Int J Lab Hematol; 2022 Oct; 44(5):831-836. PubMed ID: 35609868
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Platelet aggregation and platelet factor 3 activity in myeloproliferative disorders.
    Tangün Y
    Thromb Diath Haemorrh; 1971 Jun; 25(2):241-51. PubMed ID: 5284903
    [No Abstract]   [Full Text] [Related]  

  • 50. The histamine content of granulocytes, as a possible characteristic of myelocytic leukaemia.
    BIKICH G; BORBOLA J; TANOS B; KELEMEN E
    Acta Med Acad Sci Hung; 1953; 4(1):17-34. PubMed ID: 13039937
    [No Abstract]   [Full Text] [Related]  

  • 51. [Diagnostic difficulties in osteomyelosclerosis with myeloid metaplasia in relation to the other components of the myeloproliferative syndrome].
    Vilcu A; Hossu T; Popescu ID; Câmpeanu L
    Med Interna (Bucur); 1973 Mar; 25(3):363-76. PubMed ID: 4527026
    [No Abstract]   [Full Text] [Related]  

  • 52. [Granulocyte clearance and granulocyte kinetics in myeloproliferative syndromes].
    Jungi WF; Meuret G; Senn HJ
    Schweiz Med Wochenschr; 1974 Jan; 104(4):133-5. PubMed ID: 4521299
    [No Abstract]   [Full Text] [Related]  

  • 53. Muramidase activity in leukemia and myeloproliferative disorders.
    Skarin AT; Matsuo Y; Moloney WC
    Oncology; 1973; 27(5):406-14. PubMed ID: 4515747
    [No Abstract]   [Full Text] [Related]  

  • 54. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.
    Bianco E; Marcucci F; Mele A; Musto P; Cotichini R; Sanpaolo MG; Iannitto E; De Renzo A; Martino B; Specchia G; Montanaro M; Barbui AM; Nieddu R; Pagano L; Rapicetta M; Franceschi S; Mandelli F; Pulsoni A;
    Haematologica; 2004 Jan; 89(1):70-6. PubMed ID: 14754608
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Leukocyte histidine decarboxylase: properties and activity in myeloproliferative disorders.
    Krauss S; Gilbert HS; Wasserman LR
    Blood; 1968 Jun; 31(6):699-709. PubMed ID: 5240758
    [No Abstract]   [Full Text] [Related]  

  • 56. A patient with basophilic-eosinophilic myeloproliferative disorder showing monosomy 7 and hyperhistaminemia.
    Takimoto Y; Imanaka F; Hayashi Y; Shindo H
    Acta Haematol; 1997; 98(1):37-41. PubMed ID: 9210912
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Leukocyte function in chronic myeloproliferative disorders.
    Wolach B; Gavrieli R; Manor Y; Lishner M
    Blood Cells Mol Dis; 1998 Dec; 24(4):544-51. PubMed ID: 9887281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
    Hsu HC; Tan LY; Au LC; Lee YM; Lieu CH; Tsai WH; You JY; Liu MD; Ho CK
    J Lab Clin Med; 2004 Feb; 143(2):125-9. PubMed ID: 14966468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Significance of circulating megakaryocytes in chronic myeloproliferative syndromes.
    Hanganu E; Iordăcheanu L; Popa G
    Rev Med Chir Soc Med Nat Iasi; 1983; 87(3):377-8. PubMed ID: 6587496
    [No Abstract]   [Full Text] [Related]  

  • 60. Histamine excess symptoms in basophilic chronic granulocytic leukemia.
    Youman JD; Taddeini L; Cooper T
    Arch Intern Med; 1973 Apr; 131(4):560-2. PubMed ID: 4121666
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.